



COMPANY OVERVIEW

Cardax is a consumer health company focused on marketing ZanthoSyn[®], a physician recommended astaxanthin dietary supplement for inflammatory health.* Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration.

RECENT NEWS

Cardax Announces Breakthrough Longevity Results with ZanthoSyn[®] in NIH-Funded Study

Dec 6 2023, 3:00 PM EST

Cardax Refocuses on ZanthoSyn[®] Consumer Health Business

Aug 31 2021, 6:18 PM EDT

STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	1
Last Price	\$0.000001
52-Week Range	\$0.000001 - \$0.0011
12/27/2023 09:38 AM EST	

INVESTOR RELATIONS

Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com

MANAGEMENT TEAM

David G. Watumull
Chairman and CEO

David M. Watumull
COO and CFO

CARDAX, INC.

2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.